Business, energy, technology, markets and global industry news from Business News Today

VS-7375

PharmaDeviceNews VS-7375
Verastem Oncology has dosed the first patient in the TARGET-D 203 Phase 2 trial evaluating VS-7375 for KRAS G12D-mutated metastatic colorectal cancer, advancing its registration-directed precision oncology programme. Representative image.
Pharma & Biotech

Verastem has opened its KRAS G12D colorectal cancer trial, but the real test is still ahead

Verastem has started TARGET-D 203, testing VS-7375 alone and in combinations for KRAS G12D metastatic colorectal cancer.

Read More
Verastem Oncology advances its VS-7375 development programme as the TARGET-D 202 Phase 2 trial begins evaluating the investigational KRAS G12D inhibitor in previously treated advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

Verastem has entered the KRAS G12D lung cancer race, but can VS-7375 close the evidence gap?

Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.

Read More
Pharma & Biotech

Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?

Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.

Read More
Pharma & Biotech

Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets

Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.

Read More